NSPR
InspireMD Q2 2026 Revenue $1.8 Million
InspireMD reported $1.8 million in Q2 2026 revenue and announced a voluntary U.S. recall of the CGuard Prime 135 cm delivery system.
NSPR news
Latest 2 stories · newest Aug 17, 2026
NSPR
InspireMD reports 100% device success in CGuard Prime TCAR trial
InspireMD announced positive 30-day results from CGUARDIANS II trial showing 100% acute device success with zero major adverse events for its CGuard Prime 80cm stent in TCAR procedures. The company expects FDA approval in H2 2026, potentially expanding its addressable market to include transcarotid …
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same NSPR feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/NSPR/newsSTART FREE